Investing in a global pooled-funding mechanism for late-stage clinical trials of poverty-related and neglected diseases: an economic evaluation.
Armand ZimmermanMohamed Mustafa DiabMarco SchäferhoffKaci Kennedy McDadeGavin YameyOsondu OgbuojiPublished in: BMJ global health (2023)
All 3 options for a pooled-funding mechanism-vaccines for 4 PRNDs, vaccines and therapeutics for 9 PRNDs, and vaccines, therapeutics and diagnostics for 30 PRNDs-would generate a large return on investment, avert a substantial proportion of the global burden of morbidity and mortality for diseases of poverty and be cost-effective.